Last updated: 2026-10-13 07:29:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Zevra Therapeutics, Inc. (ZVRA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $11,34, with a market capitalisation of $676,38M and a P/E ratio of 11,61. Over the past 52 weeks, its price has ranged from $8,01 to $15,04. This page covers its latest market performance, valuation, price trends and company information.
$676,38M | |
$11,39 | |
$15,04 | |
$3,89 | |
$11,39 | |
412,67K | |
1,09M | |
11,61 | |
$15,04 | |
$8,01 | |
-- | |
-- |
Zevra Therapeutics, Inc. (ZVRA) last closed at $11,39 as of 2026-10-12 23:57:00, unchanged from the previous close of $11,39.
During the latest regular trading session, ZVRA traded between $3,89 and $15,04, with a volume of 412,67K shares. The closing price was near the upper end and near the middle of its 52-week range.
Over the past seven days, Zevra Therapeutics, Inc. (ZVRA) moved from $9,99 to $11,34, representing a gain of 13,46% ($1,35).
The stock traded between $9,85 and $11,56 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 886,80 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 47,3%
ZVRA is currently trading at $11,34, placing it 47,3% of the way from its 52-week low of $8,01 to its 52-week high of $15,04. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 61 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Zevra Therapeutics, Inc. (ZVRA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.